Logo image of FUSN

FUSION PHARMACEUTICALS INC (FUSN) Stock Fundamental Analysis

NASDAQ:FUSN - Nasdaq - CA36118A1003 - Common Stock - Currency: USD

21.55  +0.03 (+0.14%)

After market: 21.65 +0.1 (+0.46%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to FUSN. FUSN was compared to 572 industry peers in the Biotechnology industry. While FUSN seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, FUSN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

FUSN had negative earnings in the past year.
In the past year FUSN has reported a negative cash flow from operations.
FUSN had negative earnings in each of the past 5 years.
In the past 5 years FUSN always reported negative operating cash flow.
FUSN Yearly Net Income VS EBIT VS OCF VS FCFFUSN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

FUSN has a better Return On Assets (-32.20%) than 67.76% of its industry peers.
FUSN has a better Return On Equity (-43.12%) than 71.40% of its industry peers.
Industry RankSector Rank
ROA -32.2%
ROE -43.12%
ROIC N/A
ROA(3y)-35.1%
ROA(5y)-30.86%
ROE(3y)-43.89%
ROE(5y)-40.25%
ROIC(3y)N/A
ROIC(5y)N/A
FUSN Yearly ROA, ROE, ROICFUSN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

FUSN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FUSN Yearly Profit, Operating, Gross MarginsFUSN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 -2K -4K -6K

More info and screens

5

2. Health

2.1 Basic Checks

FUSN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for FUSN has been increased compared to 1 year ago.
Compared to 5 years ago, FUSN has more shares outstanding
Compared to 1 year ago, FUSN has an improved debt to assets ratio.
FUSN Yearly Shares OutstandingFUSN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 20M 40M 60M
FUSN Yearly Total Debt VS Total AssetsFUSN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

An Altman-Z score of 11.27 indicates that FUSN is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 11.27, FUSN belongs to the best of the industry, outperforming 86.83% of the companies in the same industry.
FUSN has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
FUSN has a worse Debt to Equity ratio (0.21) than 68.28% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Altman-Z 11.27
ROIC/WACCN/A
WACC8.38%
FUSN Yearly LT Debt VS Equity VS FCFFUSN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

FUSN has a Current Ratio of 10.64. This indicates that FUSN is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 10.64, FUSN is doing good in the industry, outperforming 78.16% of the companies in the same industry.
FUSN has a Quick Ratio of 10.64. This indicates that FUSN is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of FUSN (10.64) is better than 78.16% of its industry peers.
Industry RankSector Rank
Current Ratio 10.64
Quick Ratio 10.64
FUSN Yearly Current Assets VS Current LiabilitesFUSN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 28.64% over the past year.
FUSN shows a strong growth in Revenue. In the last year, the Revenue has grown by 124.18%.
EPS 1Y (TTM)28.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.11%
Revenue 1Y (TTM)124.18%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 4.89% on average over the next years.
FUSN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 86.49% yearly.
EPS Next Y-0.46%
EPS Next 2Y-7.92%
EPS Next 3Y-5.8%
EPS Next 5Y4.89%
Revenue Next Year-82.55%
Revenue Next 2Y-57.46%
Revenue Next 3Y57.91%
Revenue Next 5Y86.49%

3.3 Evolution

FUSN Yearly Revenue VS EstimatesFUSN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
FUSN Yearly EPS VS EstimatesFUSN Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

FUSN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FUSN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FUSN Price Earnings VS Forward Price EarningsFUSN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FUSN Per share dataFUSN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

A cheap valuation may be justified as FUSN's earnings are expected to decrease with -5.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.92%
EPS Next 3Y-5.8%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FUSN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FUSION PHARMACEUTICALS INC

NASDAQ:FUSN (6/3/2024, 8:16:08 PM)

After market: 21.65 +0.1 (+0.46%)

21.55

+0.03 (+0.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2024-05-07/bmo
Earnings (Next)08-06 2024-08-06/amc
Inst Owners1.12%
Inst Owner Change-40.5%
Ins Owners4.3%
Ins Owner Change0%
Market Cap1.83B
Analysts70
Price Target21.55 (0%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-9.41%
Min EPS beat(2)-13.32%
Max EPS beat(2)-5.51%
EPS beat(4)2
Avg EPS beat(4)5.99%
Min EPS beat(4)-13.32%
Max EPS beat(4)38.59%
EPS beat(8)4
Avg EPS beat(8)-0.1%
EPS beat(12)7
Avg EPS beat(12)-0.91%
EPS beat(16)7
Avg EPS beat(16)-41.79%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)424.39%
Min Revenue beat(4)-100%
Max Revenue beat(4)1958.04%
Revenue beat(8)4
Avg Revenue beat(8)334.79%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.17%
PT rev (3m)47.07%
EPS NQ rev (1m)-3.22%
EPS NQ rev (3m)-5.78%
EPS NY rev (1m)-1.56%
EPS NY rev (3m)-4.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)457.68%
Revenue NY rev (1m)-25.29%
Revenue NY rev (3m)-27.93%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 898.55
P/FCF N/A
P/OCF N/A
P/B 7.58
P/tB 7.58
EV/EBITDA N/A
EPS(TTM)-1.42
EYN/A
EPS(NY)-1.71
Fwd EYN/A
FCF(TTM)-1.03
FCFYN/A
OCF(TTM)-0.98
OCFYN/A
SpS0.02
BVpS2.84
TBVpS2.84
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -32.2%
ROE -43.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.1%
ROA(5y)-30.86%
ROE(3y)-43.89%
ROE(5y)-40.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 278.83%
Cap/Sales 196.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.64
Quick Ratio 10.64
Altman-Z 11.27
F-Score4
WACC8.38%
ROIC/WACCN/A
Cap/Depr(3y)253.63%
Cap/Depr(5y)230.57%
Cap/Sales(3y)146.05%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.11%
EPS Next Y-0.46%
EPS Next 2Y-7.92%
EPS Next 3Y-5.8%
EPS Next 5Y4.89%
Revenue 1Y (TTM)124.18%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-82.55%
Revenue Next 2Y-57.46%
Revenue Next 3Y57.91%
Revenue Next 5Y86.49%
EBIT growth 1Y-19.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-33.12%
EBIT Next 3Y-12.65%
EBIT Next 5YN/A
FCF growth 1Y-22.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.34%
OCF growth 3YN/A
OCF growth 5YN/A